Summary of Ultralife Corporation Q1 2026 Earnings Call

1Key Financial Results and Metrics

Revenue: $47.4 million, down from $50.7 million in Q1 2025.

Operating Loss: $0.2 million, compared to an operating income of $3.4 million in the previous year.

Net Loss: $0.5 million or $0.03 per share, down from a net income of $1.9 million or $0.11 per share in Q1 2025.

Gross Profit: $10.1 million, a 20.7% decline year-over-year; gross margin at 21.3%, down from 25.1%.

Backlog: Record high of $115.1 million, a 21.1% increase year-over-year, with over $12 million from new products.

Adjusted EBITDA: $3.2 million or 6.8% of sales, down from $5.4 million or 10.7% in the prior year.

2Strategic Updates and Business Highlights

Product Development: Continued investment in new products across both Battery & Energy and Communication Systems segments. Notable projects include a conformal wearable battery and a tactical network hub.

Leadership Changes: New experienced leadership in manufacturing facilities aimed at improving efficiencies and gross margins.

Brand Realignment: Ongoing efforts to unify under the Ultralife brand for clearer messaging.

Growth Initiatives: Focus on vertical integration post-Electrochem acquisition, with plans to double the use of internal cells in packs.

3Forward Guidance and Outlook

Priorities for 2026:

Improve revenue capture in the Communication Systems business.

Enhance gross margins, particularly in the Newark operation.

Continue vertical integration and product development.

Complete brand alignment by year-end.

Market Positioning: Strong backlog and ongoing product launches position the company for potential revenue growth in the coming quarters.

4Bad News, Challenges, or Points of Concern

Declining Sales: Notable decreases in revenue from both Battery & Energy Products (4.7% decline) and Communication Systems (25.7% decline).

Production Issues: Significant lost production days due to various operational challenges, including weather events and facility reorganizations, which negatively impacted gross margins.

Increased Operating Expenses: Operating expenses rose 10.5% year-over-year, driven by one-time costs and increased product development expenses.

Market Risks: Concerns over global economic conditions, military spending fluctuations, and potential delays in product acceptance.

5Notable Q&A Insights

No questions were raised during the Q&A session, indicating either a lack of immediate investor concerns or a need for further clarity on the discussed topics. This summary encapsulates the key points from Ultralife Corporation's Q1 2026 earnings call, highlighting both the challenges faced and the strategic initiatives in place to drive future growth.